Subscribe to RSS
DOI: 10.1160/TH11-09-0611
Infections and inflammatory diseases as risk factors for venous thrombosis
A systematic reviewPublication History
Received:
06 September 2011
Accepted after major revision:
24 January 2012
Publication Date:
25 November 2017 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/201205/lookinside/thumbnails/10-1160-th11-09-0611-1.jpg)
Summary
Inflammation and venous thrombosis are intertwined. Only in the recent 15 years clinical epidemiological studies have focussed on inflammatory or infectious diseases as risk factors for venous thrombosis. Although a few reviews and many case reports or studies on these topic has been written, a review reporting relative or absolute risks for venous thrombosis has not been published yet. We performed a systematic review using Medline, Pubmed and Embase and found 31 eligible articles. Inflammatory bowel disease, ANCA-associated vasculitis, infections in general and more specifically, human immunodeficiency virus, pneumonia and urinary tract infections are associated with an increased risk of venous thrombosis.
-
References
- 1 Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-1173.
- 2 Lijfering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous thrombosis - current understanding from an epidemiological point of view. Br J Haematol 2010; 149: 824-833.
- 3 Cermak J, Key NS, Bach RR. et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-520.
- 4 van der Poll T, Büller HR, ten Cate H. et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622-1627.
- 5 Tabib A, Greenland T, Mercier I. et al. Coronary lesions in young HIV-positive subjects at necropsy. Lancet 1992; 340: 730.
- 6 Abgueguen P, Delbos V, Chennebault JM. et al. Vascular thrombosis and acute cy-tomegalovirus infection in immunocompetent patients: report of 2 cases and literature review. Clinical Infectious Diseases 2003; 36: E134-139.
- 7 Wells G, Shea B, OConnell D. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
- 8 Seriolo B, Accardo S, Garnero A. et al. Anticardiolipin antibodies, free protein S levels and thrombosis: a survey in a selected population of rheumatoid arthritis patients. Rheumatology 1999; 38: 675-678.
- 9 Miehsler W, Reinisch W, Valic E. et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?. Gut 2004; 53: 542-548.
- 10 Alikhan R, Cohen AT, Combe S. et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004; 164: 963-968.
- 11 Matta F, Singala R, Yaekoub AY. et al. Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost 2009; 101: 134-138.
- 12 Bernstein CN, Blanchard JF, Houston DS. et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001; 85: 430-434.
- 13 Huerta C, Johansson S, Wallander M-A. et al. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007; 167: 935-943.
- 14 Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103: 2272-2280.
- 15 Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010; 375: 616-617.
- 16 Novacek G, Weltermann A, Sobala A. et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010; 139: 779-787 787.e771.
- 17 Ludvigsson JF, Welander A, Lassila R. et al. Risk of thromboembolism in 14,000 individuals with coeliac disease. Br J Haematol 2007; 139: 121-127.
- 18 Crawshaw AP, Wotton CJ, Yeates DGR. et al. Evidence for association between sarcoidosis and pulmonary embolism from 35-year record linkage study. Thorax 2011; 66: 447-448.
- 19 Stassen PM, Derks RPH, Kallenberg CGM. et al. Venous thromboembolism in ANCA-associated vasculitis – Incidence and risk factors. Rheumatology 2008; 47: 530-534.
- 20 Merkel PA, Lo GH, Holbrook JT. et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 2005; 142: 620-626.
- 21 Weidner S, Hafezi-Rachti S, Rupprecht HD. Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2006; 55: 146-149.
- 22 Sullivan PS, Dworkin MS, Jones JL. et al. Epidemiology of thrombosis in HIV-infected individuals. The Adult/Adolescent Spectrum of HIV Disease Project. AIDS 2000; 14: 321-324.
- 23 Fultz SL, McGinnis KA, Skanderson M. et al. Association of venous thromboembolism with human immunodeficiency virus and mortality in veterans. Am J Med 2004; 116: 420-423.
- 24 Naess IA, Christiansen SC, Romundstad P. et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 05: 692-699.
- 25 White RH, Zhou H, Murin S. et al. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost 2005; 93: 298-305.
- 26 White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 1998; 128: 737-740.
- 27 Lijfering WM, Kate MK, Sprenger HG. et al. Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy. J Thromb Haemost 2006; 04: 1928-1930.
- 28 Matta F, Yaekoub AY, Stein PD. Human immunodeficiency virus infection and risk of venous thromboembolism. Am J Med Sci 2008; 336: 402-406.
- 29 Malek J, Rogers R, Kufera J. et al. Venous thromboembolic disease in the HIV-infected patient. Am J Emerg Med 2010; Am J Emerg Med 2011; 29: 278-282.
- 30 Lijfering WM, de Vries APJ, Veeger NJGM. et al. Possible contribution of cytomegalovirus infection to the high risk of (recurrent) venous thrombosis after renal transplantation. Thromb Haemost 2008; 99: 127-132.
- 31 Atzmony L, Halutz O, Avidor B. et al. Incidence of cytomegalovirus-associated thrombosis and its risk factors: a case-control study. Thromb Res 2010; 126: e439-443.
- 32 Tichelaar VYIG, Sprenger HG, Mäkelburg ABU. et al. Active cytomegalovirus infection in patients with acute venous thrombosis: A case-control study. Am J Hematol 2011; 86: 510-512.
- 33 van Wissen M, Keller TT, Ronkes B. et al. Influenza infection and risk of acute pulmonary embolism. Thromb J 2007; 05: 16.
- 34 Zhu T, Carcaillon L, Martinez I. et al. Association of influenza vaccination with reduced risk of venous thromboembolism. Thromb Haemost 2009; 102: 1259-1264.
- 35 Lozinguez O, Arnaud E, Belec L. et al. Demonstration of an association between Chlamydia pneumoniae infection and venous thromboembolic disease. Thromb-Haemost 2000; 83: 887-891.
- 36 Koster T, Rosendaal FRDD. et al. Chlamydia pneumoniae IgG seropositivity and risk of deep-vein thrombosis. Lancet 2000; 355: 1694-1695.
- 37 Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics 1995; 51: 228-235.
- 38 Farrington CP. Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine 2004; 22: 2064-2070.
- 39 Farrington P, Pugh S, Colville A. et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995; 345: 567-569.
- 40 Smeeth L, Cook C, Thomas S. et al. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 2006; 367: 1075-1079.
- 41 Gangireddy C, Rectenwald JR, Upchurch GR. et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg 2007; 45: 335-342.
- 42 Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160: 3415-3420.
- 43 Cimminiello C, Filippi A, Mazzaglia G. et al. Venous thromboembolism in medical patients treated in the setting of primary care: A nationwide case-control study in Italy. Thromb Res 2010; 126: 367-372.
- 44 Tichelaar YIGV, Knol HM, Mulder AB. et al. Association between deep vein thrombosis and transient inflammatory signs and symptoms: a case-control study. J Thromb Haemost 2010; 08: 1874-1876.
- 45 Bhagat K, Moss R, Collier J. et al. Endothelial „stunning“ following a brief exposure to endotoxin: a mechanism to link infection and infarction?. Cardiovasc Res 1996; 32: 822-829.
- 46 Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997; 96: 3042-3047.
- 47 Hooper WC, Phillips DJ, Ribeiro MJ. et al. Tumor necrosis factor-alpha downregulates protein S secretion in human microvascular and umbilical vein endothelial cells but not in the HepG-2 hepatoma cell line. Blood 1994; 84: 483-489.
- 48 Johnson K, Aarden L, Choi Y. et al. The proinflammatory cytokine response to coagulation and endotoxin in whole blood. Blood 1996; 87: 5051-5060.
- 49 Riewald M, Ruf W. Science review: role of coagulation protease cascades in sepsis. Crit Care 2003; 07: 123-129.
- 50 van Aken BE, den Heijer M, Bos GM. et al. Recurrent venous thrombosis and markers of inflammation. Thromb Haemost 2000; 83: 536-539.
- 51 van Aken BE, Reitsma PH, Rosendaal FR. Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis. Br J Haematol 2002; 116: 173-177.
- 52 van Deventer SJ, Büller HR, ten Cate JW. et al. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76: 2520-2526.
- 53 Borissoff JI, Spronk HMH, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364: 1746-1760.
- 54 Levi M, Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-592.
- 55 Levi M, van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004; 109: 2698-2704.
- 56 Hein TW, Singh U, Vasquez-Vivar J. et al. Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis 2009; 206: 61-68.
- 57 Müller MM, Griesmacher A. Markers of endothelial dysfunction. Clin Chem Lab Med 2000; 38: 77-85.
- 58 Stouthard JM, Levi M, Hack CE. et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996; 76: 738-742.
- 59 Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
- 60 Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-1812.
- 61 Szalai AJ, Agrawal A, Greenhough TJ. et al. C-reactive protein: structural biology and host defense function. Clin Chem Lab Med 1999; 37: 265-270.
- 62 Bisoendial RJ, Kastelein JJP, Levels JHM. et al. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res 2005; 96: 714-716.
- 63 Chen C, Nan B, Lin P. et al. C-reactive protein increases plasminogen activator inhibitor-1 expression in human endothelial cells. Thromb Res 2008; 122: 125-133.
- 64 Singh U, Devaraj S, Jialal I. C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol 2005; 25: 2216-2221.
- 65 Molins B, Peña E, Vilahur G. et al. C-reactive protein isoforms differ in their effects on thrombus growth. Arterioscler Thromb Vasc Biol 2008; 28: 2239-2246.
- 66 Wu J, Stevenson MJ, Brown JM. et al. C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo significance. Arterioscler Thromb Vasc Biol 2008; 28: 698-704.